New York biologics regulations.

Who may administer PRP, exosomes and stem cells in New York, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in New York?

In New York, only licensed medical professionals, such as physicians with MD or DO credentials, are authorized to administer stem cell therapies. Additionally, practitioners must meet all state-mandated licensing and certification requirements to deliver these therapies legally.

Official sources

New York compliance guide.

FDA Compliance

Biologic treatments, including stem cell therapies, are regulated under the FDA's Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) framework. Clinics must ensure that any HCT/P they provide meets FDA guidelines, particularly if the products fall under section 361 of the Public Health Service Act. Compliance with FDA regulations ensures the safety and efficacy of biologic treatments offered to patients.

New York State Regulations

New York state-specific regulations governing biologics and stem cell therapies can be accessed through the New York State Department of Health. Familiarity with these guidelines is essential, as New York mandates strict adherence to health protocols for biologics. Clinics should regularly check for updates to ensure ongoing compliance with any new requirements.

Provider Qualifications

In New York, only licensed medical professionals, such as physicians with MD or DO credentials, are authorized to administer stem cell therapies. Additionally, practitioners must meet all state-mandated licensing and certification requirements to deliver these therapies legally. To confirm licensing requirements, consult the New York State Education Department's Office of the Professions.

Patient Informed Consent

Prior to administering any biologic treatment, providers must secure informed consent from the patient. This consent should detail the potential risks, benefits, and alternative treatments available, and clearly state that stem cell therapy is not FDA-approved for all uses, making it experimental in nature. Properly documented consent minimizes liability and ensures ethical practices.

Pre-Treatment and Post-Treatment Protocols

Clinics should establish clear pre-treatment and post-treatment protocols. Pre-treatment assessments can help determine the patient's suitability, while post-treatment monitoring ensures safety and addresses any complications that may arise. Detailed SOPs enhance patient care and maintain regulatory compliance.

Medical Liability Insurance

Clinics offering biologic therapies must carry medical liability insurance covering such treatments. Ensuring adequate insurance coverage mitigates potential financial risks associated with patient complications or claims related to these therapies.

Marketing Compliance

Marketing of biologic treatments in New York must comply with both FDA and state advertising guidelines. Claims should be truthful, non-misleading, and avoid guaranteeing outcomes. Clinics should review the FDA's guidance on health fraud and marketing to ensure advertising materials meet compliance standards.

This guide is a general summary to help clinics understand compliance requirements for biologics in New York. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

New York: common questions.

Who can administer stem cells, PRP and exosomes in New York?
In New York, only licensed medical professionals, such as physicians with MD or DO credentials, are authorized to administer stem cell therapies. Additionally, practitioners must meet all state-mandated licensing and certification requirements to deliver these therapies legally. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in New York?
FDA rules are federal, so they apply in New York as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in New York?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in New York?
Start with the live webinar, then a discovery call and live training. After that we verify your New York licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in New York? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.